Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 6/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.39 |
| ▸ | NSD2 | O96028 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25519380 | 0.88 | NLRP3 (0.50) | EGLN2CYP11B2CYP11B1HSP90AB1NLRP3 | |
| SCHEMBL25519458 | 0.83 | EGLN2 (0.41) | EGLN2CYP11B2CYP11B1HSP90AB1NSD2 | |
| SCHEMBL20116875 | 0.76 | ALDH1A1 (0.45) | EGLN2CYP11B2CYP11B1SLC22A12 | |
| SCHEMBL2154193 | 0.75 | CYP11B2 (0.53) | EGLN2CYP11B2CYP11B1SLC22A12 | |
| SCHEMBL25856432 | 0.73 | NLRP3 (0.38) | NLRP3 | |
| SCHEMBL3364120 | 0.73 | EGLN2 (0.47) | EGLN2CYP11B2CYP11B1HSP90AB1NSD2 | |
| SCHEMBL25859518 | 0.72 | NLRP3 (0.37) | NLRP3 | |
| SCHEMBL3366217 | 0.71 | KCNH2 (0.52) | EGLN2CYP11B2CYP11B1KCNH2 | |
| SCHEMBL17630059 | 0.71 | EGLN2 (0.47) | EGLN2CYP11B2CYP11B1HSP90AB1NSD2 | |
| SCHEMBL25856428 | 0.71 | NLRP3 (0.36) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023088987-A1 | PYRIDAZINE DERIVATIVES AS INHIBITORS OF NLRP3 | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-25 | — | — | WO | disclosed |